Introduction
============

The prevalence of tobacco use and nicotine addiction among persons with schizophrenia in America is known to be substantially higher than among the general population. Tobacco use rates of 70%--90% have been reported for persons with schizophrenia, compared with approximately 23% in the overall United States population ([@b17]; [@b14]; [@b21]; [@b33]; [@b19]; [@b3]). Unfortunately, persons with schizophrenia are subject to the same tobacco-related health risks as other tobacco users. As a result, tobacco-related death rates among this population reflect its high prevalence of tobacco use ([@b5]; [@b6]; [@b24]).

Standard smoking cessation therapies are effective in helping smokers with schizophrenia quit smoking. Motivational group sessions ([@b2]), NRT ([@b33]; [@b13]), and bupropion ([@b11]) all appear to be useful in reducing smoking in this population. However, when these therapies are completed, the relapse rates after six months are significant. [@b2] reported that six months after the completion of seven weekly group sessions, the "quit" rate had decreased approximately 70%. Following a three-month treatment with NRT, George et al (2000) reported "quit" rates to decrease by 50%--70%. Similarly, [@b11] reported a 60% decrease in quit rates six months following a nine-week treatment with bupropion. Comparable relapse rates in the general population average approximately 35% ([@b10]).

It has been suggested that nicotine may have a unique role(s) in the brains of persons with schizophrenia ([@b7]; [@b28]; [@b29]; [@b22]; [@b31]; [@b23]) and that this may account for the high prevalence of nicotine use by these persons. The accumulated evidence suggests that successful tobacco cessation programs for persons with schizophrenia may have to consider more than just the addiction.

[@b14] have demonstrated that in a normal population of smokers, extended treatment of the smoking cessation drug bupropion is effective in relapse prevention compared with placebo. The influence of extended pharmacological treatment on relapse rate in a population of smokers with schizophrenia has not been previously studied. Therefore, we sought to determine the feasibility and efficacy of extended NRT to help persons with schizophrenia remain tobacco-free. Nicotine replacement therapy (NRT) is known as an effective treatment for nicotine addiction ([@b33]; [@b13]) in persons with schizophrenia. We report here the results of a single-blind study in which continued NRT was compared with placebo for six months after persons with schizophrenia had successfully quit smoking through the use of NRT.

Methods
=======

Fifty volunteers with a diagnosis of schizophrenia or schizo-affective disorder were enrolled in the study. Subjects were recruited through the collaborations with local mental health support providers. Each subject gave written informed consent. In addition to the above diagnoses, each subject had to have stable psychiatric symptoms over the past two months, use tobacco daily, be between 18 and 60 years of age, and be able to participate in all of the study activities. Subjects were not included who had cancer or clinically significant cardiac, renal, gastrointestinal, pulmonary, hepatic, endocrine, hematological, or neurological diseases. Also not included were female subjects who were pregnant or breastfeeding, or any subjects who were judged to be unreliable.

Subjects provided medical and psychiatric histories and a list of concomitant medications. Each subject was given a standard 12-lead electrocardiogram, gave a blood sample for a 24-item clinical chemistry panel, and gave a saliva sample for cotinine determination. Levels of expired carbon monoxide (CO), an indicator of recent smoking, were determined with a Vitalograph-Breath Monitor (Catalog Model \#29700, Vitalograph Inc, Lenexa, Kansas, USA). Subjects were administered a Clinical Global Evaluation Scale to determine their relative levels of motivation, cognitive functioning, and schizophrenia symptoms; and they completed a modified Fagerström Test for Nicotine Addiction ([@b16]).

Following a review of the screening results by the study staff and psychiatrist, subjects were assigned to groups of no more than 10 individuals per group. The groups met with a health educator weekly for one hour for 12 weeks. During these 12 weeks, subjects were presented with a formal curriculum designed for this population and based on the "strengths model" ([@b26]). The "strengths model" is designed to help the subjects become more aware of and employ their strengths related to intelligence, competence, motivation, and communication in accomplishing their goal of quitting the use of tobacco. This model emphasizes their successes rather than failures. The health educator was experienced in working with subjects with schizophrenia and was trained in providing tobacco cessation group therapy. During regular office hours, the subjects were able to contact the health educator by phone to ask questions or to seek special assistance. Subjects were encouraged to set a quit date within the first two weeks of their participation. To minimize cravings and/or the emergence of symptoms that may be reduced by nicotine, nicotine patch doses were based on individual cotinine saliva levels. Saliva nicotine and cotinine concentrations are highly correlated with those in plasma ([@b27]). Subjects were provided with NicoDerm^®^ CQ^®^ patches at doses of 14, 21, or 42 mg/day ([@b8]). Subjects with cotinine levels less than 200 ng/mL were given 14 mg patches; those from 200 to 449 ng/mL received 21 mg patches; those from 450 to 900 ng/mL were given 42 mg (two 21 mg patches); and those above 900 ng/mL received 63 mg (three 21 mg patches). Patches were distributed to subjects at their quit date and instructions were given to refrain from smoking while using NRT. Subjects were encouraged to rotate the site of patch applications. During the first and second months some adjustments of nicotine doses were permitted to accommodate individual experiences with side effects or cravings. No changes in nicotine dosage were permitted beyond that time. At each weekly group session, subjects were monitored for expired carbon monoxide levels, smoking activity, craving levels, and NRT tolerance. Subjects with CO levels of 10 ppm or less were considered non-smokers.

A flow chart defining study phases is shown in [Figure 1](#fig1){ref-type="fig"}. Subjects who did not set a "quit" date within two weeks, who did not reduce their tobacco use by 75% after 60 days, or who did not quit 100% after 90 days were discontinued from the study. Those subjects who successfully quit tobacco use after 90 days were randomly assigned (coin flip by blinded third party) to receive either placebo patches (SmithKline Beecham Consumer, Parsippany, NJ, USA) or nicotine patches (Nicoderm^®^ CQ^®^), with no change in dose for six months. Subjects in this phase were blinded as to the type of patches they received. Subjects attended group sessions no less than every two weeks for informal education/motivational discussions with the health educator. During these sessions subjects were monitored for expired CO levels, smoking activity, craving levels, and NRT tolerance. Subjects with CO levels of less than 10 ppm were considered non-smokers. Subjects with CO levels over 10 ppm for two consecutive weeks were considered relapsed and discontinued from the study.

![Study timeline.\
^a^ Smoking quit date due at 2 weeks -- subjects discontinued if not set.\
^b^ Tobacco use to be reduced by 75% at 60 days -- subjects discontinued if not successful.\
^c^ Tobacco use to be reduced by 100% at 90 days -- subjects discontinued if not successful.](ndt0104-349-01){#fig1}

Differences in CO levels between baseline (screening levels) and last observation carried forward were analyzed by comparing means using paired t-tests (2-tailed).

For individuals who quit smoking, group differences in outcome (relapse vs non-relapse) and single-blind treatment type (active nicotine patch vs non-active placebo patch) were analyzed by comparing proportions using Fisher's exact test (2-tailed). Group differences in outcome (relapse vs non-relapse) and antipsychotic medication (on atypical vs not on atypical antipsychotic) were analyzed by comparing proportions using Fisher's exact test (2-tailed). In addition, a Kaplan-Meier Survival Analysis was conducted to analyze the relationship of single-blind treatment type and time to relapse. Significance was calculated using log-ranks.

Relationships between smoking-associated variables (pack-years, cotinine, and Fagerström rating) were assessed using Kendall's correlation coefficient for nonparametric data and Pearson's correlation coefficient for parametric data. An alpha level of 0.05 was used to designate statistical significance. All data in these analyses were tested for normality. SPSS 11.0.1 for Windows was used for all statistical analyses.

Results
=======

Characteristics of the study subjects are shown in [Table 1](#tbl1){ref-type="table"}. The population was nearly equally divided between males and females. All participants smoked cigarettes, the mean pack-years was 40 and the mean Fagerström score was 7.4. The antipsychotic medications and their chlorpromazine equivalents taken by the subjects are listed in [Table 2](#tbl2){ref-type="table"} along with their study outcomes. No discernable pattern is evident. Moreover, there was no significant effect of antipsychotic type on smoking outcome. Thirty-two were taking concomitant antidepressant medication primarily selective serotonin reuptake inhibitors. Four subjects screened were taking bupropion (150 mg/day); one did not return for participation, two did not totally quit smoking and consequently did not participate in the single-blind phase of the study, and the fourth was included in the single-blind nicotine patch group but relapsed after two months.

###### 

Subject characteristics

                                                               Mean    SD      Range                                         Frequencies n = 50
  ------------------------------------------------------------ ------- ------- --------------------------------------------- --------------------
  Age                                                          42.5    10.1    21--65                                        
  Sex                                                                                                                        24 (48%) female
                                                                                                                             26 (52%) male
  Pack years                                                   39.9    28.4    1.3--112.0                                    
  Fagerstrom                                                   7.4     1.5     4.0--10.0                                     
  Baseline cotinine level                                      476.4   392.0   0.0[b](#tf1-2){ref-type="table-fn"}--2094.0   
  Baseline carbon monoxide level                               29.9    21.3    1.0--110.0                                    
  Taking antipsychotic?[a](#tf1-1){ref-type="table-fn"}                                                                      44 (100%) yes
  Taking any Antidepressant?[a](#tf1-1){ref-type="table-fn"}                                                                 32 (72.7%) yes

Six cases missing who discontinued participation.

One subject quit smoking shortly before study initiation.

###### 

Frequencies of antipsychotic medications by study progress

                        Total   Chlorpromazine equivalent: Average mg/day (range) \[SD\]   Single-blind participants                          Reduced smoking by 75%, but failed to reduce by 100%   Failed to reduce smoking by 75%   Discontinued participation
  --------------------- ------- ---------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------ --------------------------------- ----------------------------
  Risperidone           18      165.2 (50--400) \[SD = 99.5\]                              4 (22.2%) \[3\][a](#tf2-1){ref-type="table-fn"}    9 (50.0%)                                              2 (11.1%)                         3 (16.7%)
  Olanzapine            11      266.7 (100--500) \[SD = 134.7\]                            4 (36.4%) \[2\][a](#tf2-1){ref-type="table-fn"}    5 (45.5%)                                              0 (0.0%)                          2 (18.2%)
  Clozapine             10      447.3 (60--1000) \[SD = 398.7\]                            5 (50.0%) \[3\][a](#tf2-1){ref-type="table-fn"}    1 (10.0%)                                              0 (0.0%)                          4 (40.0%)
  Quetiapine fumarate   6       426.8 (267--667) \[SD = 173.8\]                            1 (16.7%) \[1\][a](#tf2-1){ref-type="table-fn"}    3 (50.0%)                                              0 (0.0%)                          2 (33.3%)
  Ziprasidone           6       95.8 (17--133) \[SD = 54.8\]                               2 (33.3%) \[2\][a](#tf2-1){ref-type="table-fn"}    1 (16.7%)                                              0 (0.0%)                          3 (50.0%)
  Fluphenazine HCl      4       666.7 (500--1000) \[SD = 288.7\]                           1 (25.0%) \[0\][a](#tf2-1){ref-type="table-fn"}    1 (25.0%)                                              0 (0.0%)                          2 (50.0%)
  Haloperidol           2       5000.0 (5000--5000) \[SD = 0\]                             0 (0.0%) \[0\][a](#tf2-1){ref-type="table-fn"}     1 (50.0%)                                              0 (0.0%)                          1 (50.0%)
  Chlorpromazine HCl    2       300.0 (300--300) \[SD = 0\]                                1 (50.0%) \[1\][a](#tf2-1){ref-type="table-fn"}    1 (50.0%)                                              0 (0.0%)                          0 (0.0%)
  Trifluoperazine HCl   1       1000.0 (1000--1000) \[SD = 0\]                             1 (100.0%) \[1\][a](#tf2-1){ref-type="table-fn"}   0 (0.0%)                                               0 (0.0%)                          0 (0.0%)
  Aripiprazole          1       300.0 (300--300) \[SD = 0\]                                1 (100.0%) \[0\][a](#tf2-1){ref-type="table-fn"}   0 (0.0%)                                               0 (0.0%)                          0 (0.0%)
  None                  3       --                                                         2 (66.7%) \[1\][a](#tf2-1){ref-type="table-fn"}    1 (33.3%)                                              0 (0.0%)                          0 (0.0%)

Indicates number relapsed.

Chlorpromazine equivalents adapted from [@b20]; [@b32].

Six subjects were taking an antichloinergic (5 benztropine, 1 trihexyphenidyl). Of these, two were included in the single-blind phase. One subject on placebo relapsed. The other on active patch remained tobacco-free to the conclusion of the study. Of the 50 subjects enrolled: 10 failed to return for group sessions and did not receive NRT; two withdrew from the study for personal reasons prior to starting NRT; four failed to reduce their smoking rate by 75% within 60 days and were discontinued from the study; 16 failed to quit smoking completely by 90 days and were discontinued from the study; and 18 quit smoking and advanced to the single-blind extension (see [Table 3](#tbl3){ref-type="table"} for the characteristics of these groups). None of the subjects who began NRT discontinued the study because of adverse events, and none had any significant problem with skin rash at the patch sites. Of the 42 subjects who used NRT, one used 63 mg, 18 used 42 mg, 16 used 21 mg, and seven used 14 mg doses. Of those who participated in the single-blind phase, four used 42 mg, nine used 21 mg, and three used 14 mg doses. Of the four subjects on 42 mg in single-blind, two relapsed and two remained abstinent.

###### 

Smoking characteristics of each study group

                                                                            Fagerstrom rating   Pack years                              Baseline cotinine level                 Baseline carbon monoxide level   Final carbon monoxide level
  ------------------------------------------------------------------ ------ ------------------- --------------------------------------- --------------------------------------- -------------------------------- -----------------------------
  Discontinued participation (n = 12)                                Mean   8.0                 30.2                                    548.5[a](#tf3-1){ref-type="table-fn"}   20.4                             20.1
  SD                                                                 1.2    27.4                447.3[a](#tf3-1){ref-type="table-fn"}   18.4                                    13.6                             
  Failed to reduce smoking by 75% (n = 4)                            Mean   7.8                 42.5                                    449.5                                   36.5                             36.8
  SD                                                                 1.5    35.2                177.0                                   17.6                                    16.1                             
  Reduced smoking by 75%, but failed to reduce by 100% (n = 16)      Mean   6.8                 46.2                                    596.8                                   34.6                             27.0
  SD                                                                 1.4    33.9                515.4                                   26.0                                    15.1                             
  Reduced smoking by 100%, but relapsed (n = 11)                     Mean   7.7                 37.9                                    274.8                                   30.3                             20.2
  SD                                                                 1.5    16.9                146.9                                   15.1                                    7.6                              
  Reduced smoking by 100% and maintained non-smoking state (n = 7)   Mean   7.3                 44.0                                    420.3                                   30.9                             1.6
  SD                                                                 1.8    30.2                230.9                                   24.4                                    2.4                              
  Single-blind subjects receiving nicotine (n = 9)                   Mean   7.8                 43.0                                    418.1                                   35.9                             11.1
  SD                                                                 1.2    25.2                201.2                                   23.3                                    14.3                             
  Single-blind subjects receiving placebo (n = 8)                    Mean   7.8                 33.8                                    236.8                                   26.1                             21.1
  SD                                                                 1.6    18.0                152.5                                   11.4                                    15.0                             

One case missing.

The results of the single-blind portion of the study are shown in [Figure 2](#fig2){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}. All eight of the subjects on placebo patches relapsed within six months, while three of nine subjects on nicotine patches relapsed. The difference in smoking status between the placebo and active patch groups was statistically significant at the p = 0.009 level (Fisher 2-tailed test) and p ≤ 0.005 (log ranks). [Figure 2](#fig2){ref-type="fig"} shows a substantial divergence in relapse between the two treatment groups after two months of the single-blind phase. The criterion for relapse was defined as two consecutive measurements of CO above ten parts per million. [Table 5](#tbl5){ref-type="table"} shows the number of months at which this criterion was reached for each of the relapsed subjects and the number of single episodes of CO measurements above 10 ppm prior to reaching the relapse criterion. All of the relapsed subjects showed evidence of intermittent smoking activity prior to relapse while the smoke-free subjects consistently had CO levels below 10 ppm.

![Comparison of time to relapse across treatment groups. The differences seen in Figure 2 illustrate the effect of treatment type on time to relapse. Subjects in the placebo group relapsed sooner than the nicotine group with a 0.0% non-relapse at 6 months, and subjects in the nicotine group had 66.7% non-relapse at 6 months. This effect is statistically significant (logrank = 8.09, df = 1, p \< 0.005).](ndt0104-349-02){#fig2}

###### 

Relationship of nictotine or placebo patch and smoking status[a](#tf4-1){ref-type="table-fn"}

                              Relapsed   Non-relapse   Total
  ---------------- ---------- ---------- ------------- ------------------------------------
  Nicotine patch   observed   3          6             9
  Placebo patch    observed   8          0             8
  Total                       11         6             17[b](#tf4-2){ref-type="table-fn"}

Fisher's exact (2-tailed) = 0.009.

One individual who reduced smoking by 100% stopped using any patch, and therefore is not included in either nicotine or placebo group.

###### 

Total number of CO measures \> 10 in single-blind phase per subject

               Month relapsed (of 6)   \#CO's \> 10
  ------------ ----------------------- --------------
  *Placebo*                            
  2005         5                       6
  4011         3                       3
  5010         2                       3
  2011         4                       2
  5003         1                       2
  2012         2                       2
  3008         6                       2
  2001         3                       2
  *Nicotine*                           
  3003         --                      0
  5006         --                      0
  5001         --                      0
  3005         --                      0
  4014         --                      0
  3002         --                      0
  5009         6                       2
  2009         2                       2
  3009         3                       5

**Abbreviations:** CO, carbon monoxide.

Dashes denote participants who did not relapse.

Five subjects on their own volition attempted to reduce or discontinue the use of patches during the initial phase of the study. One subject remained tobacco-free throughout the study without using patches. That individual was not included in these analyses.

No significant correlation was observed between baseline cotinine levels and Fagerström ratings or pack-years. No significant differences were observed among the groups shown in [Table 2](#tbl2){ref-type="table"} with the exception of the final CO levels that were significantly reduced in the individuals who remained smoke-free throughout the single-blind phase of the study.

Discussion
==========

The results of this pilot study are encouraging. Approximately two-thirds of the subjects reduced their tobacco consumption by 75% within 60 days, and approximately one-third quit completely within 90 days. This compares favorably to quit rates previously reported in subjects with schizophrenia using nicotine patches and group therapies in open label protocols ([@b2]; [@b13]). The significant difference in relapse rates between placebo and active patch groups offer particularly promising support for long-term NRT in persons with schizophrenia who have quit using tobacco, although the small sample size requires that our conclusions be considered tentative. With a similarly designed study, [@b14] have shown that long-term treatment with bupropion after smoking cessation also reduces the rate of relapse in a normal population.

Although this study was conducted in a single blind fashion, the fact that the primary end point, CO levels in expired air, is an objective measure along with the robust response, suggest that the results are worthy of further verification.

The contents of the education/support group sessions were not formally evaluated; however, based on clinical observations they did appear to play a role in the participants' success by providing opportunities for mutual support and encouragement, and providing focus seemed to contribute to success. Nevertheless, the group sessions alone were not adequate in preventing relapses.

The high prevalence of tobacco use among persons with schizophrenia is widely discussed. Perhaps less appreciated is the high level of addiction as evidenced by high Fagerström nicotine dependence scores. The average Fagerström score found in this study was 7.4. This compares with scores of approximately 2.5--4.5 in nonschizophrenic populations ([@b9]; [@b18]). Scores reported in subjects with schizophrenia range from 5.6 to 9.04 ([@b1]; [@b12]; [@b25]; [@b4]; [@b30]). In two studies that compared scores between subjects with and without schizophrenia, those with schizophrenia had significantly higher Fagerström scores ([@b4]; [@b30]). Another study reported higher scores for smokers with schizophrenia than those without, but the difference was not significant ([@b12]). Overall, subjects with schizophrenia appear to have higher than normal Fagerström nicotine dependence scores. In spite of a high dependence level, persons with schizophrenia do have a desire and motivation to give up tobacco ([@b1]), but may require continued smoking cessation therapies to help them achieve long-term success.

The results of this preliminary study suggest additional investigations. First, confirmation of these results in a larger number of subjects and for a longer duration would be useful for determining the practical significance of these findings. Second, information on the cost/benefit of long-term therapy must be evaluated. Is the cost of the program justified by improvements in the health of the individuals with a concomitant reduction in healthcare costs and morbidity?
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